These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17240042)

  • 1. Editorial comment on: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    Montironi R
    Eur Urol; 2007 Sep; 52(3):768. PubMed ID: 17240042
    [No Abstract]   [Full Text] [Related]  

  • 2. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
    Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
    van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
    J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
    Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
    Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
    Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
    Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
    Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic markers for urothelial cancer: obstacles and opportunities.
    Malmström PU
    Urol Oncol; 2012; 30(4):516-7. PubMed ID: 22742563
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.
    Knowles MA
    Future Oncol; 2008 Feb; 4(1):71-83. PubMed ID: 18241002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
    Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
    Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
    López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
    Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
    Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
    J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    Malats N; Real FX
    Eur Urol; 2009 Mar; 55(3):658. PubMed ID: 18584942
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    Burger M
    Eur Urol; 2009 Mar; 55(3):657. PubMed ID: 18584941
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
    Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
    Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
    Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
    Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.